These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 34077510)

  • 21. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
    J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B; Mingardi G; Braun J; Aljama P; Kerr PG; Locatelli F; Villa G; Van Vlem B; McMahon AW; Kerloëguen C; Beyer U;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3654-61. PubMed ID: 18586762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
    Akizawa T; Yamaguchi Y; Majikawa Y; Reusch M
    Ther Apher Dial; 2021 Oct; 25(5):575-585. PubMed ID: 33200512
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD.
    Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S
    Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
    Akizawa T; Iwasaki M; Otsuka T; Yamaguchi Y; Reusch M
    Kidney Int Rep; 2021 Jul; 6(7):1810-1828. PubMed ID: 34307976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
    JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
    Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
    Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.
    Hou YP; Mao XY; Wang C; Xu ZH; Bu ZH; Xu M; Li B
    J Formos Med Assoc; 2022 Feb; 121(2):529-538. PubMed ID: 34167878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.
    Besarab A; Chernyavskaya E; Motylev I; Shutov E; Kumbar LM; Gurevich K; Chan DT; Leong R; Poole L; Zhong M; Saikali KG; Franco M; Hemmerich S; Yu KH; Neff TB
    J Am Soc Nephrol; 2016 Apr; 27(4):1225-33. PubMed ID: 26494833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India.
    Mazahir R; Anand K; Pruthi PK
    Eur J Pediatr; 2023 Jan; 182(1):101-109. PubMed ID: 36220980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R; Besarab A; Sun CH; Diamond SA; Durham JH; Cangiano JL; Aiello JR; Novak JE; Lee T; Leong R; Roberts BK; Saikali KG; Hemmerich S; Szczech LA; Yu KP; Neff TB
    Clin J Am Soc Nephrol; 2016 Jun; 11(6):982-991. PubMed ID: 27094610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
    Zhang L; Hou J; Li J; Su SS; Xue S
    Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N; Hao C; Peng X; Lin H; Yin A; Hao L; Tao Y; Liang X; Liu Z; Xing C; Chen J; Luo L; Zuo L; Liao Y; Liu BC; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1001-1010. PubMed ID: 31340089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
    Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
    Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
    N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
    Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
    Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
    Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
    N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Clin Exp Nephrol; 2022 Sep; 26(9):843-850. PubMed ID: 35462610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.